| Summary: | The disease Leishmaniasis is a neglected illness with two major forms clinically including cutaneous
leishmaniasis and visceral leishmaniasis. From almost 100 endemic countries, an estimated one million
additional records of leishmaniasis each year are documented. In the past decade, the number of confirmed
cases of visceral leishmaniasis has decreased dramatically as a consequence of an improved approach to
diagnosis and care and more intensive, though usual cycles may play a role in the severity of disease
transmission. In the cutaneous form of leishmania disease (CL), the lesion is located in some parts like the face
and arms. Whereas a visceral form of leishmania (VL) disease the parasite infects internal organs such as the
liver and pancreas. Reports from the World Health Organization (WHO) record leishmaniasis as one of the
ignored temperate disorders for which the improvement of novel therapies is required. Significant evidence
gaps remain, and new methods are required before leishmaniasis can be definitively managed. Recent advances
in our understanding of leishmaniasis and its clinical manifestations, as well as the immunological aspects of
leishmaniasis, are the key objectives of this study.
|
|---|